Table 1.
Baseline characteristics of systemic AL amyloidosis patients.
| Characteristic | Systemic AL amyloidosis (n = 575) |
|---|---|
| Male—n (%) | 370 (64) |
| Female—n (%) | 205 (36) |
| Concomitant symptomatic multiple myeloma—n (%) | 45 (8) |
| Amyloid light chain subtype | |
| Kappa—n (%) | 169 (24) |
| Lambda—n (%) | 406 (71) |
| Organ involvement at diagnosis | |
| Renal—n (%) | 394 (69) |
| Cardiac—n (%) | 306 (53) |
| Peripheral or autonomic neuropathy—n (%) | 105 (18) |
| GI—n (%) | 89% (15) |
| Liver—n (%) | 66 (11) |
| At diagnosis | |
| Median 24 h urine proteinuria—mg (IQR) | 2168 (808–5795) |
| Median urine monoclonal protein—mg (IQR) | 0 (0–175) |
| Median serum creatinine—mg/dL (IQR) | 1.1 (0.9–1.5) |
| Median dFLC at diagnosis—mg/L (IQR)a | 188 (68–551) |
| dFLC < 10 mg/L—n (%) | 28 (5) |
| dFLC > 1000 mg/L—n (%) | 42 (7) |
| Bone marrow plasma cell burden—% (IQR) | 10 (5–19) |
| At urine collection | |
| Age—years (IQR) | 65 (59–71) |
| Median UACR—mg/g (IQR) | 211 (19–2516) |
| Median spot urine albumin—mg/L (IQR) | 170 (17–2129) |
| Median 24 h urine proteinuria—mg (IQR) | 447 (141–3059) |
| Median eGFR—mL/min/1.73m2 (IQR)b | 57 (34–74) |
| Median time between 24hUP and uACR—days (IQR) | 0 (0–1) |
| Median time between diagnosis and uACR collection—months (IQR) | 24 (0.9–77) |
| AM (before noon) UACR collection time—n (%) | 346 (60) |
| PM (after noon) UACR collection time—n (%) | 229 (40) |
| BMI—kg/m2 (IQR) | 26.1 (23.4–29.7) |
adFLC difference in the involved to uninvolved free light chain.
beGFR was calculated using the CKD-EPI formula, which incorporates age, sex, race, and serum creatinine26. Given our patient demographic, we assumed that all patients were non-African American.
Bold values indicate statistical significance.